BCL2A1 Recombinant Rabbit monoclonal Antibody IgG
Fig1: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-BCL2A1 antibody. Counter stained with hematoxylin.
Fig2: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti- BCL2A1 antibody. Counter stained with hematoxylin.
Fig3: Immunohistochemical analysis of paraffin-embedded mouse liver tissue using anti- BCL2A1 antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityRabbit; Human, Mouse, Rat
Application SummaryWB, IHC, FC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesBcl-2-related protein A1, Bcl-2-like protein 5, Hemopoietic-specific early response protein, Protein BFL-1, Protein GRS
BackgroundThe Bcl-2 family of proteins is characterized by its ability to modulate cell death under a broad range of physiological conditions. Bcl-2 and Bcl-xL function to inhibit apoptosis while other members of the Bcl-2 family, Bax, Bad, Bak and Bcl-xS, oppose death-suppressing effects. An additional member of the family, A1 (also designated Bfl-1), dimerizes with both Bcl-2 and Bax and has been identified as a hematopoietic- specific, early inducible gene. While A1 demonstrates life promoting properties similar to those of Bcl-2, its function may be more temporally regulated during myeloid differentiation and dependent on additional growth stimuli to confer its life promoting properties. A1 is abundantly expressed in bone marrow and at low levels in other tissues. There is evidence that a correlation exists between a high expression of the A1 gene product and stomach cancer.(ET1610-20)